Prostate Cancer - PSA

Prostate cancer is the most frequent malignant neoplasm in men and the second most common cancer to cause death among American men. The disease ranges from indolent malignancies, which may not need treatment, to more aggressive forms that should be treated. Current recommendations aim to guide clinicians and patients toward a balanced and individualized approach to screening to avoid unnecessary treatment while enabling early detection of aggressive prostate cancers. Such an approach to screening is especially important because of the harms associated with screening, such as false-positive results and consequent additional tests or biopsies, psychological distress, overdiagnosis, overtreatment, and adverse effects of treatment. Laboratory testing involves serum prostate-specific antigen (PSA) testing, PSA derivatives, and other biomarkers. Digital rectal examination (DRE) is not recommended for use as a standalone test but should be considered in conjunction with PSA results in men who have chosen to undergo screening for early detection of prostate cancer. Percent free PSA, PSA velocity, and PCA3, and calculations such as the Prostate Health Index (PHI), are useful for risk stratification.

Tabs Content

Clinical Overview

Quick Answers

What are current recommendations on prostate-specific antigen (PSA) screening?

The U.S. Preventive Services Task Force (USPSTF) recommended against routine prostate-specific antigen (PSA) screening in 2012; however, the 2018 USPSTF guideline states that PSA screening in men 55-69 years of age may have limited benefit for some men and recommends individualized decision-making with regard to screening. A number of other organizations offer similar recommendations. (See Societal Recommendations for Prostate Cancer Screening table below.)

Can prostate-specific antigen (PSA) results using different assays and laboratories be directly compared?

Clinicians should be aware that prostate-specific antigen (PSA) testing has not been harmonized; ie, the assay and its performance may vary between laboratories, which may lead to significant variation in results. Clinical guidelines for PSA testing may have been developed without a complete understanding of this variation. Thus, results require careful interpretation because variation in results may lead to inappropriate clinical decision-making and potentially adverse effects on patient care. Repeat PSA testing should be performed using the same assay and laboratory to maximize consistency.

What factors affect prostate-specific antigen (PSA) results?

Infection, ejaculation, trauma, recent procedures, benign conditions, and certain medications all can affect prostate-specific antigen (PSA) lab test results. See Prostate-Specific Antigen section below for additional information.

How do laboratory tests contribute to diagnosis?

Prostate-specific antigen (PSA) and other biomarker tests can help guide decisions about which patients should consider biopsy, but definitive diagnosis is based on biopsy and pathologist examination.

Prostate Cancer Early Detection Screening Algorithm

Indications for Testing

Laboratory testing for prostate cancer is appropriate in a variety of circumstances, such as for:

Screening in men who elect to undergo testing for early detection of prostate cancer
Risk stratification to aid in decisions about necessity or frequency of testing
Follow-up in men with a previously elevated PSA or suspicious DRE result
Monitoring in men undergoing active surveillance for indolent cancer
Monitoring for recurrence following treatment for prostate cancer

Laboratory Testing

A variety of laboratory and risk calculation tests are used to determine which men should consider undergoing biopsy; some of these same tests are used for prognostic assessment and for monitoring after diagnosis.

Screening

Prostate-Specific Antigen

PSA is a glycoprotein found mainly in the seminal plasma but also in the circulation, and is not specific to cancer. Recent procedures (eg, urethral, biopsy) can result in increased serum PSA levels, as can infection, ejaculation, or trauma. PSA also can be elevated in men with benign conditions, such as prostatitis and benign prostatic hyperplasia (BPH), and PSA levels can be affected (decreased) by treatment with 5-alpha reductase inhibitors. In addition, normal PSA values do not rule out prostate cancer; some men have a normal PSA result but a suspicious DRE. Despite these limitations, evidence from clinical trials still supports serum PSA testing for the timely detection of prostate cancer and to guide clinical decisions concerning biopsy. A number of organizations recommend shared decision-making, which includes discussion of age, life expectancy, and risk factors, such as family history and race, to determine when to start screening with PSA. Results of a DRE (if performed) should be considered along with the PSA result. Refer to table below for specific recommendations.

Societal Recommendations for Prostate Cancer Screening
Society	Age and Risk Category	Screening Recommendation	Screening Frequency
NCCN (2019)	≥45-75 yrs	Informed testing	1- to 2-yr intervals if PSA is ≥1.0 ng/mL^a 2- to 4-yr intervals if PSA is <1.0 ng/mL
	≥40 yrs with higher risk (African-American men or men with known or suspected cancer susceptibility gene)	Shared decision-making regarding decision to screen, evaluating risks, benefits, and personal values	1-yr intervals
	≥60 yrs with PSA <1.0 ng/mL	Risk of metastases and death as a result of prostate cancer is low; this population can consider discontinuing screening	n/a
	>75 yrs	Screening recommended only in healthy men with little or no comorbidity; widespread screening not recommended; men with PSA <3.0 ng/mL can consider discontinuing screening	4-yr interval appropriate in older men with lower PSA result; clinical judgment should be used
USPSTF, 2018	55-69 yrs, not high risk	Shared decision-making regarding screening, recognizing there is a small mortality benefit of screening that may balance risks; decision should be an individual one	Not defined due to lack of data, but mortality benefit appears to be associated with every-2-yr screening
	≥70 yrs	Screening is not recommended due to lack of mortality benefit (including for men expected to live 10-15 more yrs)	n/a
	African-American men <55 yrs	Insufficient evidence to support a separate screening recommendation specific to this population, but clinicians are advised to inform men of risk for prostate cancer and benefits/harms of screening to aid in personal decision-making
	Men <55 yrs with family history of prostate cancer
AUA (2013, reviewed and confirmed 2018)	<40 yrs, ≥70 yrs, or life expectancy <10-15 yrs	Screening not recommended due to lack of mortality benefit	n/a
	40-54 yrs, with average risk	Routine screening not recommended	n/a
	40-54 yrs, with higher risk (eg, positive family history, African American)	Shared decision-making regarding decision to screen, evaluating risks, benefits, and personal values	2-yr interval is recommended
	55-69 yrs
	≥70 yrs, in excellent health
ACS (2016)	≥50 yrs, average risk, life expectancy ≥10 yrs	Shared decision-making regarding decision to screen, evaluating risks, benefits, and personal values	2-yr interval is suggested if PSA is <2.5 ng/mL 1-yr interval is suggested if PSA is ≥2.5 ng/mL
	≥45 yrs and high risk (African American, men with first-degree relative diagnosed at an early age)
	≥40 yrs at very high risk (multiple family members diagnosed at an early age)	Shared decision-making, including discussion of risks/benefits of screening and patient preferences
	<40 yrs, or <10-yr life expectancy	Insufficient evidence to recommend screening with PSA	n/a
ASCO (2012)	≤10 yr life expectancy	Screening not recommended because harms seem to outweigh potential benefits	n/a
ASCO (2012)	>10 yr life expectancy	Shared decision-making, including discussion of risks/benefits of screening and patient preferences	n/a
^aIn the event of PSA >3 ng/mL and/or suspicious DRE, work up for benign disease and repeat testing; if PSA is ≥3 ng/mL on repeat testing, consider further testing (%fPSA, PHI, 4Kscore). AUA, American Urological Association; ACS, American Cancer Society; ASCO, American Society of Clinical Oncology; NCCN, National Comprehensive Cancer Network; %fPSA, percent free PSA Sources: NCCN, 2019; USPSTF, 2018; Carter, AUA, 2013; ACS, 2016; Basch, ASCO, 2012

Prostate-Specific Antigen Interpretation

A PSA above the median for one’s age group is associated with higher risk for prostate cancer development and with more aggressive cancer. The higher the PSA result is above the median, the higher the individual’s risk. NCCN recommends that patients with a steady and marked increase in PSA be encouraged to have a biopsy. PSA levels of 4-10 ng/mL often prompt additional testing (cancer is discovered in approximately 30-35% of men with serum PSA results in this range), but NCCN now recommends that any man with a PSA >3 ng/mL be evaluated with repeat PSA testing as well as a DRE.

For additional information concerning follow-up based on PSA test results, refer to the Prostate Cancer Early Detection Screening Algorithm.

Other Biomarker and Risk Calculation Tests

Various biomarker tests, including those based on PSA derivatives, can be used to further assess the probability of prostate cancer before proceeding with biopsy, and can therefore help select patients who should consider biopsy. Biomarker assays are also useful to assess whether biopsy should be repeated in men who have had a negative biopsy. Caution should be used in interpreting biomarker test results.

In men who have not yet undergone biopsy but have a PSA of >3 ng/mL, NCCN recommends the following three tests be considered:

%fPSA
PHI
4Kscore

In men with a negative biopsy result but a higher risk for prostate cancer (eg, because of race, family history), NCCN suggests the following five tests be considered:

PCA3
%fPSA
PHI
4Kscore
ConfirmMDX

Percent Free Prostate-Specific Antigen

The percentage of total PSA that is unbound or free (%fPSA) is clinically informative because serum fPSA is markedly reduced in men with prostate cancer. This testing is considered useful for patients with a normal DRE but total PSA results of 4-10 ng/mL; the ratio of free to total PSA helps to distinguish between cancerous and benign conditions. The risk is age dependent: The older the patient and the lower the %fPSA result, the higher the risk for prostate cancer. Evidence indicates that a %fPSA result of <25% detects 95% of prostate cancer cases.

Refer to the ARUP Laboratory Test Directory for additional information about prostate cancer probability based on %fPSA.

Prostate-Specific Antigen Velocity

PSA velocity (PSAV) is the rate of change in PSA levels over time, and is based on three or more PSA test results obtained over a period of 18 months or longer. PSAV results should be interpreted with caution because of the high biologic variability associated with individual PSA measurements. Some studies have correlated risk of death from prostate cancer with PSAV ≥0.35 ng/mL/year. NCCN recommends that PSAV be considered along with other criteria such as age, race, family history, and comorbidity when considering whether to proceed with biopsy in men with low PSA levels; PSAV is not considered helpful in the context of high PSA levels (≥10 ng/mL).

Prostate-Specific Antigen Density

PSA density (PSAD) is determined by measuring the volume of the prostate using transrectal ultrasound; it is calculated by dividing the PSA level (in ng/mL) by the prostate volume (in cc). PSAD can help differentiate between prostate cancer and benign conditions, particularly BPH, because lower PSAD values suggest BPH. However, precise measurement of PSA and prostate volume can be challenging. PSAD offers limited benefit compared with other tests but may be useful in patients with previous prostate volume measurements.

PCA3

PCA3 is a noncoding RNA specific to prostate tissue and is overexpressed in men with prostate cancer. Laboratory testing for PCA3 quantifies this overexpression in urine samples collected after DRE. PCA3 measurements are particularly helpful in determining which men may need a repeat biopsy; men with a PCA3 score of ≥25 are more likely to have prostate cancer detected on a repeat biopsy. PCA3 testing can be used in conjunction with other criteria to help determine the necessity of a repeat biopsy in men ≥50 years of age for whom a urologist would recommend a repeat biopsy based on current standard of care.

Refer to the ARUP Laboratory Test Directory for additional information about PCA3 test result interpretation.

Complexed Prostate-Specific Antigen

PSA exists in both free and complexed forms, one of which is the alpha-1-antichymotrypsin complexed form (cPSA). Clinical trial evidence indicates that the ratio of cPSA to total PSA may be informative in the same way that the %fPSA is informative. Use of cPSA has been approved for use along with DRE to detect prostate cancer in men ≥50 years of age.

Prostate Health Index

The PHI is based on a calculation that involves total PSA, fPSA, and a subcategory of free PSA called proPSA (also referred to as p2PSA). The PHI has increased sensitivity for prostate cancer detection compared with the fPSA-total PSA ratio; the PHI also correlates with cancer grade and is useful for distinguishing high-grade cancers (Gleason score ≥7) from low-grade cancers. PHI may aid in distinguishing prostate cancer from benign prostatic conditions and in detecting prostate cancer in men ≥50 years of age with total PSA values of 4-10 ng/mL and with DRE findings that are not suspicious for cancer.

Refer to the ARUP Laboratory Test Directory for additional information about prostate cancer probability based on the PHI.

4Kscore

The 4Kscore is based on a variety of characteristics, including fPSA, total PSA, human kallikrein 2, intact PSA (a type of fPSA), age, DRE results, and results of a prior biopsy. The resulting score is the probability, expressed as a percent, that a high-grade cancer (Gleason score ≥7) will be detected on biopsy. The 4Kscore test can be considered before biopsy and in men with a previous negative biopsy result who may be at increased risk for clinically relevant prostate cancer.

ConfirmMDx

ConfirmMDx is used to assess prostate cancer risk in men who are considering a repeat biopsy. The FDA has not approved the test, a multiplex epigenetic assay that measures hypermethylation of GSTP1, APC, and RASSF1 promoter regions in tissue samples. ConfirmMDx can be considered before a repeat biopsy to help determine which men are at greater risk for a cancer diagnosis and to reduce unnecessary biopsies.

Familial Risk Testing

Gene variants related to familial prostate cancer continue to be investigated, but the American College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic Counselors recommend referral to genetic counseling in the following circumstances:

Two or more cases of prostate cancer diagnosed by 55 years of age in close relatives
Three or more first-degree relatives with prostate cancer
Aggressive prostate cancer (Gleason score >7) in the patient or in a first-degree relative, and two or more breast, ovarian, and/or pancreatic cancer cases in close relatives

Testing for hereditary cancers has increased in recent years, and panels are available that include genes associated with the risk of prostate cancer (eg, BRCA1, BRCA2, ATM, MLH1, MSH2, MSH6, HOXB13, CHEK2, NBN, PALB2, RAD51D, and TP53).

NCCN recommends that individuals who meet risk criteria for certain hereditary cancer syndromes be referred to a cancer genetics professional, and that the risk associated with such syndromes be included in discussions with men about prostate cancer screening.

Diagnosis

Definitive diagnosis of prostate cancer requires biopsy and pathologist examination. Biopsy results inform subsequent evaluation, monitoring, and treatment recommendations.

Prognosis

Prostate cancer is categorized as low, medium, or high risk for disease progression and mortality based on PSA level, clinical stage, and tumor grade. Various characteristics suggest aggressive tumor behavior; these include higher PSAD (>0.10-0.15 ng/mL/cc), higher PSAV (>2 ng/mL/year), and a higher Gleason score.

Genetic and Genomic Testing

Certain gene variants have been found to play a role in outcomes such as metastasis and castration resistance. NCCN recommends that testing for variants (germline and somatic) in BRCA1, BRCA2, ATM, PALB2, and FANCA genes be considered in patients with regional or metastatic disease if testing was not already performed; patients with positive results should be referred for genetic counseling. Germline genetic testing and genetic counseling should also be considered for all men with high-risk clinically localized prostate cancer. Such testing may help guide decisions about the use of targeted treatments and/or clinical trial enrollment.

Individuals diagnosed with low risk or “favorable intermediate” risk disease may also choose to pursue testing with tumor-based molecular assays, such as Oncotype DX (not performed at ARUP Laboratories), for prognostic information, such as the risk of death if cancer is managed conservatively, or the risk of biochemical progression following specific treatment types.

Monitoring

PSA concentrations should be measured periodically to evaluate patients for disease progression during active surveillance, and PSA results should be considered in light of other clinical and radiologic evidence; an increase in PSA alone does not confirm disease progression. PSA testing every 6 months and DRE every 12 months is recommended during surveillance, unless more frequent monitoring is clinically indicated. Active surveillance may require periodic biopsies as well.

After radical prostatectomy, PSA will generally decrease to an undetectable level. Radiation therapy should also result in a low PSA concentration. A subsequent increase in PSA of ≥2 ng/mL above the PSA nadir is considered biochemical recurrence (BCR), which may precede local recurrence or metastasis by 7-8 years.

ARUP Lab Tests

Primary Screening Tests

Preferred initial screening test for prostate cancer; use in conjunction with DRE

Use to monitor patients for cancer recurrence

Results from different assay methods or kits cannot be used interchangeably

Prostate Specific Antigen, Total 0070121

Method: Quantitative Electrochemiluminescent Immunoassay

Acceptable initial test for prostate cancer screening; preferred test is total PSA in conjunction with DRE

May help in distinguishing cancer from benign conditions

Prostate Specific Antigen, Total with Reflex to Free PSA (Includes Free Percentage) 0080264

Method: Quantitative Electrochemiluminescent Immunoassay

Preferred initial screening test for prostate cancer; use in conjunction with DRE

May be used to monitor patients for cancer recurrence

Prostate Specific Antigen, Total - Medicare Screening 0070234

Method: Quantitative Electrochemiluminescent Immunoassay

Secondary Screening Tests

Do not use for initial prostate cancer screening; preferred test is PSA, total, in conjunction with DRE

May provide additional prostate cancer risk information for patients with mildly elevated total PSA and negative DRE

Alternative to PCA3 testing in indeterminate PSA cases

Results from different assay methods or kits cannot be used interchangeably

Prostate Specific Antigen, Free Percentage (Includes Free PSA and Total PSA) 0080206

Method: Quantitative Electrochemiluminescent Immunoassay

Do not use for initial prostate cancer screening; preferred test is total PSA in conjunction with DRE

Aid in the decision to repeat biopsy in men ≥50 years who have had one or more negative prostate biopsies AND for whom a repeat biopsy would be recommended by a urologist based on current standard of care

Not for use in men with atypical small acinar proliferation on most recent biopsy

PCA3 - Prostate Cancer Biomarker by Transcription-Mediated Amplification 2010102

Method: Qualitative Transcription-Mediated Amplification

Aid in detection of prostate cancer in men ≥50 years of age when used in conjunction with a DRE

May also be used as an aid to manage and monitor patients with prostate cancer

Prostate Specific Antigen, Complexed 2002930

Method: Chemiluminescent Immunoassay

Beckman Coulter phi is indicated for use as an aid in distinguishing prostate cancer from benign prostatic conditions, for prostate cancer detection in men ≥50 years of age with total PSA ≥4.0 to ≤10.0 ng/mL, and DRE findings that are not suspicious for cancer

Prostate Health Index 3000134

Method: Quantitative Chemiluminescent Immunoassay

Use to stratify risk of aggressive prostate cancer in patients 40-80 yrs with elevated PSA in whom biopsy is being considered

Do not use if prostate cancer was previously diagnosed, DRE was performed within last 4 days, any procedure or therapy was used to treat symptomatic BPH within past 6 months, any invasive urologic procedure associated with a secondary PSA evaluation was performed within past 6 months, or 5-ARI therapy was administered within past 6 months

Prostate-Specific Kallikrein, 4Kscore 2014059

Method: Electrochemiluminescent Immunoassay

Components: Total PSA, free PSA, %FPSA, intact PSA, and hK2

Do not use for initial prostate cancer screening; preferred test is total PSA in conjunction with DRE

May be used to monitor disease after radical prostatectomy

Results from different assay methods or kits cannot be used interchangeably

Prostate Specific Antigen, Ultrasensitive 0098581

Method: Quantitative Electrochemiluminescent Immunoassay

Use for patients with metastatic prostate cancer in conjunction with clinical data and imaging to monitor response to therapy and disease progression

Allow at least 7 days following administration of a doxorubicin dose before testing

Medical Experts

Contributors

Genzen, Jonathan R., MD, PhD, Chief Operations Officer, Medical Director of Automated Core Laboratory and Farmington Health Center Clinical Laboratory, at ARUP Laboratories; Associate Professor of Clinical Pathology, University of Utah

Straseski, Joely A., PhD, MS, MT(ASCP), DABCC, Medical Director, Endocrinology and Automated Core Laboratory at ARUP Laboratories; Associate Professor of Clinical Pathology, University of Utah

References

Caroll P. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection, Version 1.2019. National Comprehensive Cancer Network. Fort Washington, PA [Updated: Jan 2019; Accessed: Apr 2019]
NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, Version 4.2018. National Comprehensive Cancer Network. Fort Washington, PA [Updated: Aug 2018; Accessed: Mar 2019]
US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, Doubeni CA, Ebell M, Epling JW, Kemper AR, Krist AH, Kubik M, Landefeld S, Mangione CM, Silverstein M, Simon MA, Siu AL, Tseng C. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319(18): 1901-1913. PubMed
International Consortium for Harmonization of Clinical Laboratory Results. Measurands. [Accessed: Feb 2019]
American Association for Clinical Chemistry. The need to harmonize clinical laboratory test results: A white paper of the American Association for Clinical Chemistry. [Issued: Jul 2015; Accessed: Mar 2019]
Carter B, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL. Early detection of prostate cancer: AUA Guideline. J Urol. 2013; 190(2): 419-26. PubMed
American Cancer Society Recommendations for Prostate Cancer Early Detection. [Last revised: Apr 2016; Accessed: Mar 2019]
Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, Loblaw A, Roth B, Williams J, Nam RK. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2012; 30(24): 3020-5. PubMed
Alford AV, Brito JM, Yadav KK, Yadav SS, Tewari AK, Renzulli J. The use of biomarkers in prostate cancer screening and treatment. Rev Urol. 2017; 19(4): 221-234. PubMed
Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015; 17(1): 70-87. PubMed
Nordström T, Akre O, Aly M, Grönberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2018; 21(1): 57-63. PubMed
Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MT, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017; 2017: PubMed
Artibani W, Porcaro AB, De Marco V, Cerruto MA, Siracusano S. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int. 2018; 100(3): 251-262. PubMed

Additional Resources

Berg CD. The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context. Acta Oncol. 2011; 50 Suppl 1: 12-7. PubMed

Bradley LA, Palomaki G, Gutman S, Samson DJ, Aronson N. PCA3 Testing for the Diagnosis and Management of Prostate Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr. PubMed

Colicchia M, Morlacco A, Cheville JC, Karnes J. Genomic tests to guide prostate cancer management following diagnosis. Expert Rev Mol Diagn. 2017; 17(4): 367-377. PubMed

Duffy MJ. PSA in screening for prostate cancer: more good than harm or more harm than good? Adv Clin Chem. 2014; 66: 1-23. PubMed

Epstein JI, Egevad L, Humphrey PA, Montironi R, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014; 38(8): e6-e19. PubMed

Heidenreich A, Abrahamsson P, Artibani W, Catto J, Montorsi F, Van Poppel H, Wirth M, Mottet N, European Association of Urology. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 2013; 64(3): 347-54. PubMed

Mulhem E, Fulbright N, Duncan N. Prostate Cancer Screening. Am Fam Physician. Leawood, KS [Published: Oct 2015; Accessed: Mar 2019]

Noguez JH, Fantz CR. Pathology consultation on prostate-specific antigen testing. Am J Clin Pathol. 2014; 142(1): 7-15. PubMed

Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P, Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013; 158(10): 761-9. PubMed

Sumanasuriya S, Omlin A, Armstrong A, Attard G, Chi KN, Bevan CL, Shibakawa A, IJzerman MJ, De Laere B, Lolkema M, Lorente D, Luo J, Mehra N, Olmos D, Scher H, Soule H, Stoecklein NH, Terstappen LW, Waugh D, de Bono JS. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. Eur Urol Oncol. 2018; 1(2): 151-159. PubMed

Vaishampayan UN. Changing face of metastatic prostate cancer: the law of diminishing returns holds true. Curr Opin Oncol. 2017; PubMed

Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby E, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, Dahlgren J, Kagan J, Srivastava S, Sanda MG. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014; 32(36): 4066-72. PubMed

Resources from the ARUP Institute for Clinical and Experimental Pathology®

Guseva NV, Rokhlin OW, Glover RA, Cohen MB. P53 and the proteasome regulate androgen receptor activity. Cancer Biol Ther. 2012; 13(7): 553-8. PubMed

Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal N. Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer. 2013; 2013: 981684. PubMed

Testing Algorithms

Prostate Cancer Early Detection Screening Algorithm

Read more about Prostate Cancer Early Detection Screening Algorithm

Educational Videos

Content Review:

March 2019

Last Update: December 2019

Prostate Cancer - PSA

Quick Answers

What are current recommendations on prostate-specific antigen (PSA) screening?

Can prostate-specific antigen (PSA) results using different assays and laboratories be directly compared?

What factors affect prostate-specific antigen (PSA) results?

How do laboratory tests contribute to diagnosis?

Prostate Cancer Early Detection Screening Algorithm

Indications for Testing

Laboratory Testing

Screening

Prostate-Specific Antigen

Prostate-Specific Antigen Interpretation

Other Biomarker and Risk Calculation Tests

Percent Free Prostate-Specific Antigen

Prostate-Specific Antigen Velocity

Prostate-Specific Antigen Density

PCA3

Complexed Prostate-Specific Antigen

Prostate Health Index

4Kscore

ConfirmMDx

Familial Risk Testing

Diagnosis

Prognosis

Genetic and Genomic Testing

Monitoring

ARUP Lab Tests

Screening

Monitoring

Medical Experts

Contributors

References

Additional Resources

Resources from the ARUP Institute for Clinical and Experimental Pathology®

Prostate Cancer Early Detection Screening Algorithm

ARUP Laboratories

ARUP Websites

ARUP Consult


	[X] Topic Name Message * If ARUP Consult does not answer your test selection and interpretation questions, or if you’d like to suggest ways to improve content or usability, please leave a message for the ARUP clinical content team. Please do not include any patient-specific or personal health information (PHI) in your message. Email Address An email address is not required, but providing one allows the ARUP Consult clinical content team to respond directly. ARUP will only use your email address to respond to your feedback. See the ARUP privacy policy for more information regarding email use. Leave this field blank


	Prostate Cancer - PSA. ARUP Consult^©. Retrieved January 15, 2020, from: https://arupconsult.com/content/prostate-cancer

You are here

Prostate Cancer - PSA

Quick Answers

What are current recommendations on prostate-specific antigen (PSA) screening?

Can prostate-specific antigen (PSA) results using different assays and laboratories be directly compared?

What factors affect prostate-specific antigen (PSA) results?

How do laboratory tests contribute to diagnosis?

Prostate Cancer Early Detection Screening Algorithm

Indications for Testing

Laboratory Testing

Screening

Prostate-Specific Antigen

Prostate-Specific Antigen Interpretation

Other Biomarker and Risk Calculation Tests

Percent Free Prostate-Specific Antigen

Prostate-Specific Antigen Velocity

Prostate-Specific Antigen Density

PCA3

Complexed Prostate-Specific Antigen

Prostate Health Index

4Kscore​

ConfirmMDx

Familial Risk Testing

Diagnosis

Prognosis

Genetic and Genomic Testing

Monitoring

ARUP Lab Tests

Screening

Monitoring

Medical Experts

Contributors

References

Additional Resources

Resources from the ARUP Institute for Clinical and Experimental Pathology®

Prostate Cancer Early Detection Screening Algorithm

ARUP Laboratories

ARUP Websites

ARUP Consult

4Kscore